KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $13.6 billion.

  • Pfizer's Other Non-Current Liabilities fell 1261.48% to $13.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 billion, marking a year-over-year decrease of 1261.48%. This contributed to the annual value of $14.2 billion for FY2024, which is 1444.46% down from last year.
  • Per Pfizer's latest filing, its Other Non-Current Liabilities stood at $13.6 billion for Q3 2025, which was down 1261.48% from $13.9 billion recorded in Q2 2025.
  • Pfizer's 5-year Other Non-Current Liabilities high stood at $16.5 billion for Q4 2023, and its period low was $11.3 billion during Q3 2021.
  • Its 5-year average for Other Non-Current Liabilities is $13.3 billion, with a median of $13.3 billion in 2025.
  • Per our database at Business Quant, Pfizer's Other Non-Current Liabilities skyrocketed by 2548.56% in 2023 and then plummeted by 1444.46% in 2024.
  • Over the past 5 years, Pfizer's Other Non-Current Liabilities (Quarter) stood at $11.3 billion in 2021, then rose by 16.32% to $13.2 billion in 2022, then rose by 25.49% to $16.5 billion in 2023, then dropped by 14.44% to $14.2 billion in 2024, then dropped by 3.85% to $13.6 billion in 2025.
  • Its Other Non-Current Liabilities was $13.6 billion in Q3 2025, compared to $13.9 billion in Q2 2025 and $13.3 billion in Q1 2025.